News

Post hoc analyses of the TENAYA and LUCERNE phase 3 trials indicated important endpoints that could signal the potential for treatment interval extension.

This month in review spotlights 6 headlines, from the FDA approving sebetralsta for HAE to NICE Recommending Betula Verrucosa for Birch Tree Allergy.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

From clinical trial updates in IBD to novel research about IBS and other disorders of gut brain interaction, catch up on the latest headlines in GI.

Three-year PIONEER data show avapritinib provides lasting symptom relief in indolent systemic mastocytosis with good safety.

EYP-1901 successfully achieved an extended time to first supplemental treatment versus aflibercept, indicating a potential for further dose interval extension.

Patient responses indicate that the device is simple and easy to use, and clinical data reflects its effectiveness in recognizing hallmark signals of AMD.

The therapy was originally approved under the name Alhemo for people with hemophilia ages 12 and up without inhibitors.

FDA approves aceclidine ophthalmic solution 1.44%, revolutionizing presbyopia treatment for millions with a once-daily eye drop.

The new requirements follow a May Advisory Committee meeting that went over the latest long-term data on opioid risks.

Inclisiran can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in hypercholesterolemia.

These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.

Results from an extension study of the PHOTON trial indicate longer-lasting visual and anatomic improvements in patients receiving aflibercept 8mg versus 2mg.

A recent analysis of data from the phase 3 YOSEMITE/RHINE trials has indicated a greater reduction in hard exudates using faricimab versus aflibercept.

An online course, AllergyAware, significantly improved school personnel’s ability to recognize and manage anaphylaxis.

In a trial studying faricimab’s efficacy in Black, Hispanic/Latino, and Native American patients with DME, investigators found results consistent with the YOSEMITE/RHINE trials.

Findings confirm a significant post-pandemic rise in disorders of gut-brain interaction, including IBS and functional dyspepsia.

These pooled THRIVE-AA1 and THRIVE-AA2 study data highlight improvements in mental health among patients with alopecia given deuruxolitinib.

Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.

During this DERM 2025 interview segment, Martinez-Dulay touches on highlights from her sessions in which she explores allergic contact dermatitis.

In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.

In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.

In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.